Session 14:

Newer Targets (Part 5)

Chairs: Makoto Kuro-o, USA and Robert H. Weiss, USA

08:00 - 08:20

SMAD-3 for fibrosis

Hui Yao Lan, Hong Kong

08:20 - 08:40

Histone modifications in kidney disease

Masaomi Nangaku, Japan

08:40 - 09:00

Spleen tyrosine kinase (Syk) in inflammatory kidney disease

David Nikolic-Paterson, Australia

09:00 - 09:10

Discussion

09:10 - 09:35

Coffee Break and Poster Viewing

Session 15:

Newer Experimental Models

Chairs:Olivier Devuyst, Switzerland and Masayuki Yamamoto, Japan

09:35 - 09:55

Zebrafish for renal function and pathophysiology

Karl Tryggvason, Sweden

09:55 - 10:15

What we have learned from novel murine models of diabetic nephropathy

Charles E. Alpers, Seattle, USA

10:15 - 10:35

Humanized mouse models for kidney disease

Dorien J.M. Peters, The Netherlands

10:35 - 10:45

Discussion

Session 16:

Surrogate Biomarkers

Chairs: Joseph V. Bonventre, USA and Frank Sistare, USA

10:45 - 11:05

Proteomics classifier for CKD and its progression

Harald Mischak, UK-Germany

11:05 - 11:25

Metabolomics

Robert Weiss, USA

11:25 - 11:30

Discussion

11:30 - 12:45

Potential Industry (Lunch) Symposium 5

Session 17:

System Biology

Chairs: Mark Cooper, Australia and Karl Tryggvason, Sweden

12:45 - 13:05

Integration of experimental approaches and computational models for new therapeutic targets

John Cijiang He, USA

13:05 - 13:25

Bioinformatics for understanding diabetic nephropathy

Jonathan M. Starkey, USA

13:25 - 13:35

Discussion

Session 18:

Collaboration among Academia, Pharma and the Regulator (Part 3)

Chairs: Zhi-Hong Liu, China and Flavio Vincenti, USA

13:35 - 13:55

Approach to partnership - academia, pharma, and governmental organization: message from Taiwan

Chih-Wei Yang, Taiwan

13:55 - 14:15

Approach to partnership - academia, pharma, and governmental organization: message from Africa

Charles Swanepoel, South Africa

14:15 - 14:25

Discussion

14:25 - 14:55

Coffee Break and Poster Viewing

Session 19:

Protocols of Clinical Trials

Chairs: Carmel Hawley, Australia and Reshma Kewalramani, USA

14:55 - 15:15

The ISN ACCTs initiative

Adeera Levin, Canada

15:15 - 15:35

Common theme in failures: study design, side effects?

Dick de Zeeuw, The Netherlands

15:35 - 15:45

Discussion

15:45 - 16:00 

Close of meeting